ライフサイエンスコーパス: TTE

1 TTE achieved a higher rate of R0 resections (86.2% vs 73

2 TTE and CMR performed on the same day in 57 prospectivel

3 TTE and TEE classified the majority (82% and 85%, respec

4 TTE and TEE were performed in 105 consecutive patients w

5 TTE cells were localized in the isthmus adjacent to doub

6 TTE cells were localized to the isthmus, above and disti

7 TTE indications (appropriate [A], may be appropriate [M]

8 TTE revealed anatomic abnormalities in 33 patients, but

9 TTE RVol(AR) was calculated as Doppler left ventricular

10 TTE shortening corresponded to a reduction in inotropic

11 TTE studies were reviewed in 58 patients (35 with PD and

12 TTE was either beneficial in pN2 disease for cT3 AC + SC

13 TTE was superior in terms of higher positive likelihood

14 ysicians who ordered, on average, at least 1 TTE per month, there was a significantly lower proportio

15 Doppler (TMD), against two-dimensional (2D) TTE contrast study and the gold standard, of transesopha

16 2D-TTE can be used to help determine the need for hospital

17 2D-TTE increased specificity and sensitivity of detecting c

18 2D-TTE was characterized by sensitivity of 85.86%, specific

19 2D-TTE was obtained using the HI vision Avius ultrasound un

20 was significantly different between the 4 2D-TTE views (3.85+/-0.58, 3.87+/-0.61, 4.02+/-0.69, and 3.

21 In contrast, 2D-TTE measurements were significantly smaller and only mod

22 mensional transthoracic echocardiography (2D-TTE) in 282 patients in 4 different views (parasternal l

23 mensional transthoracic echocardiography (2D-TTE) to determine causes of acute chest pain in patients

24 Measurements of the TAD using 2D-TTE in A4C were highly feasible and reproducible and des

25 4 to April 2016, the authors assessed 14,697 TTEs for appropriateness, of which 99% were classifiable

26 Our study cohort was 55 773 TTEs corresponding to 37 843 intervals ordered by 635 pr

27 A total of 341 (72.9%) TTE and 127 (27.1%) THE were performed.

28 cal probability, 12 had technically adequate TTE studies; 10 of these (83%) were classified as either

29 METHODS AND We obtained records of all TTEs from 2001 to 2016 completed at a large echocardiogr

30 Among TTE normal subjects, 3790 subjects (2432 women, 1358 men

31 On multivariable analysis, TTE remained an independent factor for survival.

32 Comparison of PC-CMR and TTE aortic peak velocities and mean gradients resulted i

33 Correlation between multidetector CT and TTE for global function (r = 0.68) and RWM (kappa = 0.79

34 ne of three groups according to LV shape and TTE-derived mitral filling parameters.

35 blinded to the indication for the study and TTE results but not to the device source interpreted the

36 ations between the proportion of appropriate TTEs and published year (p = 0.36) for 2007 AUC, there w

37 nt increase in the proportion of appropriate TTEs in the intervention vs control group (1054 [77.6%]

38 scribed the percentage of rarely appropriate TTEs as well as the appropriate use criteria rationale f

39 ion reduced the number of rarely appropriate TTEs ordered by attending academic cardiologists.

40 ention, the proportion of rarely appropriate TTEs was significantly lower in the intervention vs cont

41 y outcome was the rate of rarely appropriate TTEs.

42 ould reduce the number of rarely appropriate TTEs.

43 TTE)=0.87+/-0.44 cm(2)) and 21 controls (AVA(TTE)=2.96+/-0.59 cm(2)) who had TTE and PC-CMR of aortic

44 We studied 53 AVS patients (AVA(TTE)=0.87+/-0.44 cm(2)) and 21 controls (AVA(TTE)=2.96+/

45 CMR3)), AVA(CMR1) values were lower than AVA(TTE) especially for higher AVA (mean bias=-0.45+/-0.52 c

46 There was concordance between TTE and TEE in 83% of all cases.

47 Although good agreement was found between TTE and continuity equation-based CMR-AVA (r>0.94 and me

48 The mean interval between TTEs was 12.4 months, 17.0 months, 18.3 months, and 17.4

49 e outcome variable was time interval between TTEs.

50 criteria and separately on the basis of both TTE and TEE findings.

51 ombus vs. mismatch) was identified in 10% by TTE and 49% by TEE (p < 0.001).

52 kelihood category by echocardiography (15 by TTE and 12 by TEE).

53 mechanism was correctly identified in 63% by TTE and in 81% by TEE (p = 0.18).

54 y of PC-CMR to detect severe AVS, defined by TTE, provided the best results for continuity equation-b

55 se, which can be prospectively identified by TTE.

56 9/10 patients and was reliably identified by TTE; the other patient had an intramyocardial course of

57 Although RVol(MR) is similar by TTE and CMR, variability in measured RVol by both approa

58 Data from 143 patients treated by TTE by one author (1989-1999) were entered into a comput

59 e are transcriptionally induced at 12 hpi by TTEs.

60 servatively identified as being modulated by TTEs within 12 h post-inoculation (hpi), 20% of which re

61 ents with gastroesophageal junction cancers, TTE can be performed with a low death rate (2.1%), a low

62 Investigators classifying TTEs were blinded to participant groupings.

63 lt, the total cost of a trial using complete TTE was greater than CMR, which was greater than limited

64 studies were performed in three conditions--TTE TMD, TTE 2D and TEE.

65 ions, a resting PFO was detected by contrast TTE in three cases.

66 Current TTE methods are relatively insensitive in PFO detection

67 trategy 3: cost $2,774, QALY 8.49) dominates TTE/TEE-guided cardioversion (strategy 2: cost $3,106, Q

68 Doppler TTE is the primary means to diagnose AVR obstruction; he

69 ructure and function during complete Doppler TTE studies.

70 s, of whom 15 596 (15%) had a normal Doppler TTE study.

71 Preoperative Doppler TTE was performed in all cases.

72 At early TTE, PPR was not observed (n = 56) or remained unchanged

73 llow-up transthoracic echocardiograms (early TTEs) were obtained within six weeks of surgery in 99.0%

74 tation (MR) in transthoracic echocardiogram (TTE) due to relative contraindications to transesophagea

75 ) have defined transthoracic echocardiogram (TTE) indications for which there is a clear lack of bene

76 VSD on initial transthoracic echocardiogram (TTE) that resolved during donor management.

77 pared a new transthoracic echocardiographic (TTE) method for detection of right to left bubble passag

78 seen on 216 transthoracic echocardiographic (TTE) studies, and their relationship to postoperative ou

79 Transthoracic echocardiographic (TTE) surveillance of patients with mitral regurgitation

80 ver, transthoracic Doppler echocardiography (TTE) remains inconclusive in a significant number of pat

81 iateness for transthoracic echocardiography (TTE) (80% [95% confidence interval (CI): 0.75 to 0.84] v

82 a systematic transthoracic echocardiography (TTE) and a 12-month course of doxycycline and hydroxychl

83 Both transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) imaging allow

84 ression with transthoracic echocardiography (TTE) and magnetic resonance imaging (MRI).

85 ther Doppler transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) have red

86 nal therapy--transthoracic echocardiography (TTE) and warfarin therapy for 1 month before cardioversi

87 ith standard transthoracic echocardiography (TTE) are not available.

88 testing with transthoracic echocardiography (TTE) are unable to undergo testing owing to poor acousti

89 f performing transthoracic echocardiography (TTE) as part of the clinical assessment of patients awai

90 ompared with transthoracic echocardiography (TTE) by using multidetector CT.

91 d by Doppler transthoracic echocardiography (TTE) from a clinical echocardiographic database of 102 8

92 c outpatient transthoracic echocardiography (TTE) have not yet been evaluated for clinical applicabil

93 e (CMR) over transthoracic echocardiography (TTE) in ischemic cardiomyopathy and nonischemic dilated

94 tic value of transthoracic echocardiography (TTE) in the detection of PFO in patients with cryptogeni

95 n to improve transthoracic echocardiography (TTE) ordering practices of physicians in training.

96 hey received transthoracic echocardiography (TTE) to detect or exclude cardiac findings with relevanc

97 imaging and transthoracic echocardiography (TTE) were performed in 18 individuals.

98 ostoperative transthoracic echocardiography (TTE) within 6 weeks of surgery.

99 arditis, (1) transthoracic echocardiography (TTE) would be most valuable in patients with an intermed

100 ter baseline transthoracic echocardiography (TTE), adult ICR mice were injected i.p. with vehicle (10

101 ss of repeat transthoracic echocardiography (TTE), and (c) whether thyroid status and therapy affecte

102 PFO include transthoracic echocardiography (TTE), transesophageal echocardiography (TEE) and transcr

103 pectively by transthoracic echocardiography (TTE).

104 vation from TFF2 mRNA transcript-expressing (TTE) cells.

105 Extended TTE achieved a higher rate of R0 resections, a higher ly

106 Time to extubation (TTE) was the primary outcome.

107 irty-day mortality rate was 6.6% (8/121) for TTE and 7.4% (9/121) for THE (P = 0.600).

108 ues (LR+ = 106.61, 95% CI = 15.09-753.30 for TTE vs LR+ = 12.62, 95% CI = 6.52-24.43 for TCD; p = 0.0

109 ) for CMR and -9 mL (95% CI, -53 to -36) for TTE.

110 face area and -10 mL (95% CI, -76 to 56) for TTE volume flow at 2 sites.

111 opriate use in imaging show improvements for TTE and CTA but not for stress imaging and TEE.

112 tantial variation in follow-up intervals for TTE assessment of mitral regurgitation, despite risk-adj

113 -96.1%), whereas the respective measures for TTE were 45.1% (95% CI = 30.8-60.3%) and 99.6% (95% CI =

114 ppler is a sensitive and specific method for TTE PFO detection that allows quantification of right to

115 At the time of referral for TTE, ultrasonographers acquired PME images first in 5 mi

116 Overly frequent TTEs can impair patient access and reduce value in care

117 Surface mucus cells were not derived from TTE cells and the progeny of the TTE lineage did not sur

118 ostic importance of information derived from TTE on long-term all-cause mortality in a selected group

119 In the matched groups, TTE was beneficial for pT3 SCC (P = 0.004), pT3 AC (P =

120 n age of 16 +/- 2.8 years; the other six had TTE for suspected congenital heart disease/musculoskelet

121 ontrols (AVA(TTE)=2.96+/-0.59 cm(2)) who had TTE and PC-CMR of aortic valve and left ventricular outf

122 dows that prevented adequate second harmonic TTE imaging were consecutively referred for MRI to diagn

123 ions and has incremental diagnostic value if TTE is inconclusive.

124 This strategy may be feasible to improve TTE utilization among cardiologists, and this type of in

125 rovider factors contributing to variation in TTE utilization and hypothesized that variation was attr

126 ed some DNA sieving ability at 0.5% (w/w) in TTE (50 mM Tris, 50 mM TAPS, 2 mM EDTA, pH 8.4) buffer.

127 TE and 21% of patients with an indeterminate TTE.

128 for 1 month before cardioversion; 2) initial TTE, followed by TEE and early cardioversion if no throm

129 strategy should consider eliminating initial TTE and carefully assess both the thromboembolic and hem

130 ejection fraction [LVEF] </=40%) on initial TTE that resolved (LVEF >/=50%) during donor management

131 ith normal LVEF (LVEF >/=55%) on the initial TTE for recipient mortality, cardiac allograft vasculopa

132 At late TTE, four patients were found to have progression of the

133 eks of surgery in 99.0% of patients and late TTEs (mean 2.1 years) in 54.3%.

134 sal response, virulence factors (most likely TTEs) targeted genes involved in phenylpropanoid biosynt

135 ter than CMR, which was greater than limited TTE.

136 trials than echocardiography, unless limited TTE is used.

137 Odds of an abnormal finding in an A or M TTE were 6 times that of R (95% confidence interval [CI]

138 ostat produced a significant delay in median TTE: 16 hours (CI, 7-22) for placebo and 20 hours (CI, 1

139 Placebo median TTE was 98 hours with 95% confidence interval (CI) of 71

140 of low magnitude (<10%) except for mediocre TTE imaging or flail leaflets (both p < 0.001).

141 Most TTEs ordered in pediatric cardiology clinics were for in

142 nce of IE in 19% of patients with a negative TTE and 21% of patients with an indeterminate TTE.

143 E) was performed in patients with a negative TTE and a rapid rise of phase I immunoglobulin G titers.

144 A normal TTE was based on normal cardiac structure and function d

145 y sought to determine the appropriateness of TTE as currently performed in pediatric cardiology clini

146 ine estimates of morbidity from TEE, cost of TTE, cost of hospital admission for cardioversion and ut

147 analysis was used to estimate the effect of TTE measures on all-cause mortality.

148 both sensitivity and specificity measures of TTE, TCD, or both compared to the gold standard of TEE.

149 n timely surveillance and overutilization of TTE in valvular disease provides a model to study variat

150 The sensitivity of TTE for detecting IE was 32%, and the specificity was 10

151 tic yield of TCD appears to outweigh that of TTE.

152 study identified differences in the yield of TTE based on patient age and most common indications rat

153 tric cardiology clinics, diagnostic yield of TTE for various AUC indications, and any gaps in the AUC

154 ith 20% of providers deemed overutilizers of TTEs and 25% underutilizers.

155 o sports participation risk were observed on TTE in 11 of 510 participants (prevalence, 2.2%).

156 from patients undergoing initial outpatient TTE in 6 centers.

157 based educational intervention on outpatient TTE ordering by cardiologists and primary care providers

158 ional intervention on ordering of outpatient TTEs by attending academic cardiologists.

159 designed to reduce the number of outpatient TTEs that were deemed to be rarely appropriate by publis

160 intervention aimed at reducing rA outpatient TTEs.

161 Overall, TTE was similar between groups.

162 ergoing intraoperative TEE and postoperative TTE had preoperative characteristics similar to the over

163 On postoperative TTE, 40% () continued to have at least moderate MR (3 to

164 n intermediate or high clinical probability, TTE should be the diagnostic procedure of choice.

165 a collection of Type III effector proteins (TTEs) directly into the plant cell that function to over

166 e was a significantly lower proportion of rA TTEs in the intervention versus the control group (8.6%

167 tional intervention reduced the number of rA TTEs ordered by attending physicians in a variety of amb

168 The mean proportion of rA TTEs was significantly lower in the intervention versus

169 ary outcome measure was the proportion of rA TTEs.

170 After reperfusion, TTE was performed and hearts were collected for infarct

171 33%) and diagnosed only upon TEE or a second TTE in 7 (10%).

172 he PME image results when obtaining standard TTE images.

173 50%) during donor management on a subsequent TTE.

174 was higher (P=0.001) between CMR (0.99) than TTE readers (0.89).

175 tant volume (RVol) is more reproducible than TTE.

176 Diagnostic accuracy was higher for TEE than TTE for all end points (p < 0.001), but the difference w

177 There was no difference in the TTE ordering volume between the intervention and control

178 erived from TTE cells and the progeny of the TTE lineage did not survive beyond 200 days.

179 These TTE indices were more important at predicting outcome th

180 were performed in three conditions--TTE TMD, TTE 2D and TEE.

181 and whether THE is a valuable alternative to TTE regarding oncological doctrine and overall survival.

182 Alternatives to TTE have been proposed because of the reportedly high ra

183 (LR- = 0.04, 95% CI = 0.02-0.08) compared to TTE (LR- = 0.55, 95% CI = 0.42-0.72; p < 0.001).

184 (mean difference: -4.9+/-10%) as compared to TTE (P<0.01).

185 more sensitive but less specific compared to TTE for the detection of PFO in patients with cryptogeni

186 (AUC = 0.98, 95% CI = 0.97-0.99) compared to TTE studies (AUC = 0.86, 95% CI = 0.82-0.89).

187 nal prognostic stratification as compared to TTE, which may have direct impact on the indication of i

188 nce in the prediction of MACE as compared to TTE-LVEF resulting in net reclassification improvement o

189 tive patients undergoing both transthoracic (TTE) echocardiography and transesophageal (TEE) echocard

190 erval (CI) of 71 to 142 compared to Triostat TTE at 55 hours with CI of 44 to 92.

191 patients included in the analysis underwent TTE before their procedure.

192 All patients underwent TTE and CMR, and left ventricle end-diastolic volume, le

193 nderwent a tricuspid valve surgery and using TTE (A4C) in 66 healthy volunteers.

194 orrelation was similar for CMR (0.94) versus TTE readers (0.90 for the proximal isovelocity surface a

195 tients with an intermediate probability when TTE either does not yield an adequate study or indicates

196 with prosthetic valves and in those in whom TTE indicated an intermediate probability; these constit

197 ients who have prosthetic valves and in whom TTE is either technically inadequate or indicates an int

198 velocities, and gradients in agreement with TTE.

199 d severe AVS and were in good agreement with TTE.

200 quantification (r = 0.83), as compared with TTE (r = 0.68).

201 Compared with TTE, CMR has lower intraobserver and interobserver varia

202 Saline contrast with TTE using native tissue harmonics or transmitral pulsed

203 del, TEE-guided early cardioversion, without TTE, is a reasonable cost-saving alternative to conventi